Wolverine Trading
MRSN

Wolverine Trading’s Mersana Therapeutics MRSN Stock Holding History

Wolverine Trading’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-576
Closed -$18.3K – 4936
2023
Q3 		$18.3K Sell
576
-308
-35% -$14.6K ﹤0.01% 4326
2023
Q2 		$70.7K Sell
884
-72
-8% -$10.5K ﹤0.01% 3865
2023
Q1 		$96K Buy
+956
New +$134K ﹤0.01% 3677

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wolverine Trading's MRSN Position: Q1 2025 in Review

Wolverine Trading sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 435 shares — an estimated $15.4K sold.

Wolverine Trading first reported a position in MRSN in Q1 2023 and held it in 2 quarters. The position peaked at $41K in Q1 2023. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Wolverine Trading reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wolverine Trading sold 435 Mersana Therapeutics shares in Q1 2025, an estimated $15.4K.
  • Wolverine Trading first reported a position in Mersana Therapeutics in Q1 2023 and held it in 2 quarters.
  • Wolverine Trading's Mersana Therapeutics position peaked at $41K in Q1 2023.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.